Krka’s prescription pharmaceuticals sales tumbled by 12% to €340.9m ($416m) in the first quarter, following an “extraordinary” Q1 last year on the back of the first wave of the coronavirus pandemic, with management insisting the two quarters were incomparable.
“In the first quarter of 2020, Krka [as a group] realized 22% growth of sales, which was ahead of competition...




